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1. Introduction
During tumorigenesis, the primary 
tumor (PT) releases factors including 
cytokines and exosomes that modify 
not only the local tumor microenviron-
ment (TME), but also immune cell popu-
lations at a systemic level to promote 
invasion and metastasis.[1,2] Primary 
tumors are sites of chronic inflamma-
tion, where immune cells (indicated as 
CD45+) such as inflammatory mono-
cytes (indicated as Ly6C+F4/80−), mac-
rophages (indicated as F4/80+CD11b+), 
and dendritic cells (indicated as CD11c+) 
are recruited and modulated phenotypi-
cally to promote tumor cell invasion and 
metastasis.[2] Specifically, recruited tumor-
associated macrophages (TAMs, indicated 
as F4/80+CD11b+VCAM+) and resident 
TAMs (indicated as F4/80+CD11b+VCAM−) 
are known to temper CD8+ T-cell activity 
and recruit T-regulatory cells to suppress 
antitumor immunity.[3] PTs also mobi-
lize myeloid precursor cells in the bone 
marrow to traffic to sites such as the lungs, 
Primary tumor (PT) immune cells and pre-metastatic niche (PMN) sites are 
critical to metastasis. Recently, synthetic biomaterial scaffolds used as PMN 
mimics are shown to capture both immune and metastatic tumor cells. Herein, 
studies are performed to investigate whether the scaffold-mediated redirection 
of immune and tumor cells would alter the primary tumor microenvironment 
(TME). Transcriptomic analysis of PT cells from scaffold-implanted and mock-
surgery mice identifies differentially regulated pathways relevant to invasion and 
metastasis progression. Transcriptomic differences are hypothesized to result 
from scaffold-mediated modulations of immune cell trafficking and phenotype 
in the TME. Culturing tumor cells with conditioned media generated from 
PT immune cells of scaffold-implanted mice decrease invasion in vitro more 
than two-fold relative to mock surgery controls and reduce activity of invasion-
promoting transcription factors. Secretomic characterization of the conditioned 
media delineates interactions between immune cells in the TME and tumor cells, 
showing an increase in the pan-metastasis inhibitor decorin and a concomitant 
decrease in invasion-promoting chemokine (C-C motif ) ligand 2 (CCL2) in 
scaffold-implanted mice. Flow cytometric and transcriptomic profiling of PT 
immune cells identify phenotypically distinct tumor-associated macrophages 
(TAMs) in scaffold-implanted mice, which may contribute to an invasion-
suppressive TME. Taken together, this study demonstrates biomaterial scaffolds 
systemically influence metastatic progression through manipulation of the TME.
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liver, and brain, where they differentiate into myeloid-derived 
suppressor cells (MDSCs, indicated as Gr1hiCD11b+Ly6C− cells) 
that further prepare the “soil” of the organ microenvironment 
for tumor cell colonization.[4–7] This conditioned site, known as 
the pre-metastatic niche (PMN),[8] assists metastatic tumor cells 
in extravasation from the circulation and supports survival of 
the new metastatic colony until it “awakens” from a dormant 
state to become a secondary malignancy.[9]
More recently, biomaterial scaffolds have been used as 
engineered PMNs to intercept immune cells, leading to the 
capture of early metastatic cells at the implant site.[10–18] The 
recruitment of metastatic cells at the implant is mediated in 
part by immune cells. All biomaterial implants have a foreign 
body response upon implantation, with initial recruitment of 
innate immune cells such as neutrophils, macrophages, and 
dendritic cells that release cytokines and chemokines at the 
scaffold and induce microenvironmental changes.[19,20] These 
immune cell dynamics were recently investigated for scaffolds 
implanted into a healthy mouse, with inoculation of tumor 
cells after 30 d.[16] For transplantation into healthy mice, an 
initial dynamic immune population consisting mostly of mac-
rophages and monocytes was observed, which subsequently 
stabilized after 14 d.[16] Following inoculation of tumor cells, the 
immune populations within the scaffold changed substantially. 
Gr1hiCD11b+Ly6C− cells were notably absent from the scaf-
fold of healthy mice and were ≈20% of leukocytes present at 
the scaffold in tumor-bearing mice. Moreover, mice implanted 
with scaffolds had a survival benefit over mock-surgery mice, 
with reduced metastatic tumor burden at the liver and brain 
and MDSC burden at the spleen and PT. Since ablation of 
Gr1hiCD11b+Ly6C− cells removed the survival benefit conferred 
by the scaffold, we hypothesize that the interception of immune 
cell types that condition the PMN (such as Gr1hiCD11b+Ly6C− 
cells) is a mechanism whereby the scaffold influences disease 
progression.
Analogous to immune cells establishing PMNs in target 
organs, immune cells recruited to the PT participate in remod-
eling the proximal TME and impact subsequent tumor progres-
sion. In addition to interactions with local resident immune 
cells, the PT also mobilizes and recruits myeloid and inflamma-
tory monocyte precursors. Within the TME, these differentiate, 
respectively, into Gr1hiCD11b+Ly6C− MDSCs and TAMs that 
repress anti-tumor immunity and support tumor invasion and 
metastasis.[7,21] The TME is heterogeneous, and pathogenesis 
results from various changes in cell–extracellular matrix (ECM) 
interactions, paracrine signaling with surrounding tumor-sup-
portive cells, changes in oxygen/nutrient supply, and biome-
chanical cues.[22] Immune cells recruited to the PT contribute 
to the initiation of tumor cell epithelial-to-mesenchymal tran-
sition (EMT), motility, and eventual invasion.[2] Immune cells 
also “prime” tumor cells for escape into the vasculature, thus 
increasing their chances of survival and colonization to a target 
organ site.[23] Within the PT, various immune cell populations 
either promote or suppress tumor progression through direct 
contact with tumor cells or through secretion of chemokines and 
cytokines.[24,25] Given that recruited immune cells in the TME 
influence tumor progression, it follows that systemic changes to 
the trafficking patterns of these immune cells would impact the 
TME and, consequently, the tumor.
In this paper, we postulate that biomaterial scaffolds, by 
modulating immune cell trafficking and phenotype, can influ-
ence the TME at a PT, resulting in inhibition of tumor progres-
sion. We hypothesize that alterations in immune cell trafficking 
induced by the scaffold may alter the phenotype of immune cells 
at the PT, which may contribute to the reduced disease burden 
observed in prior studies.[15,16] Using an orthotopic mouse 
model of MDA-MB-231BR breast cancer, we implanted micro-
porous poly(lactide-co-glycolide) (PLG) scaffolds in the intraperi-
toneal fat and characterized tumor and TME alterations. PTs 
were obtained from tumor-inoculated mice with and without 
scaffolds (termed scaffold and mock mice, respectively). We 
analyzed the transcriptomes of PT cells isolated from scaffold 
and mock mice and identified relevant signaling pathways asso-
ciated with the gene expression profiles. From CD45+ immune 
cells isolated from the PT, we generated conditioned media, 
which modulated invasion of tumor cells in vitro. Secreted fac-
tors in these CD45+ cells and associated signaling pathways 
modulating invasion in the tumor cells were analyzed using a 
combination of secretomics and TRanscriptional Activity CEll 
aRray (TRACER) technologies. Finally, immune cell populations 
at the PT were analyzed by flow cytometry and gene expression 
profiles to determine the origin and phenotype of the immune 
cells in the absence or presence of a scaffold. Collectively, this 
work elucidates a role for engineered PMNs in modulating PT 
activity and suggests that systemic manipulation of immune cell 
dynamics and distribution may provide new insights and thera-
peutic avenues for metastatic breast cancer.
2. Results
2.1. Transcriptomes Reveal Invasion-Associated Signaling  
Pathways Differentially Regulated in Scaffold Mice
We hypothesized that the scaffold may impact the cells within 
the PT based on our prior observations of scaffold-medi-
ated reduction in metastatic burden in vivo.[15,16] MDA-MB-
231BR cells were harvested from the PT of mock and scaffold 
mice, and RNA sequencing (RNAseq) was used to analyze 
the transcriptome of the tumor cells (Figure 1A). A total of 
29,157 genes were mapped to the reference genome from reads 
in both mock and scaffold cDNA samples. After comparing the 
reads per kilobase per million mapped (RPKM) read values, 
892 genes were shown to be differentially expressed in tumor 
cells in response to the scaffold implant (p < 0.01). A volcano 
plot was generated to visualize the significant differences of 
each gene, as well as the log-fold change calculated from the 
average RPKM triplicate values from mock and scaffold PT 
cDNA samples (Figure 1B; Table S1, Supporting Information).
Up- and downregulated genes (p < 0.01, false discovery 
rate (FDR) < 0.1) were analyzed using gene ontology (GO) 
approaches to determine enriched pathways in Metascape as 
a strategy to obtain the most relevant up- and downregulated 
signaling pathways in response to the scaffold. Metascape iden-
tified 20 clusters of differentially regulated molecular functions 
among upregulated genes (Figure 1C) and 18 clusters among 
downregulated genes (Figure 1D). Downregulated enriched 
pathways and GO molecular functions traditionally associated 
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with cancer metastasis included regulation of cell motility, 
nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) signaling, and cytokine signaling in the immune 
system (Figure 1D). A subset of these genes specific to NFκB 
signaling and cell motility (Table S2, Supporting Information) 
were validated by reverse transcription polymerase chain reac-
tion (RT-PCR), with 5/7 following the same trends toward 
down- or upregulation as the RNAseq data (Table S3, Sup-
porting Information).
2.2. Conditioned Media from TME Immune Cells Alter  
Tumor Cell Invasion In Vitro
We hypothesized that scaffold-induced changes in the tumor 
cell phenotype between scaffold and mock conditions may 
be mediated in part by immune cells in the TME. The con-
tribution of the TME to tumor cell function was assessed in 
vitro following collection of conditioned media from CD45+ 
immune cells present at the PT in mock and scaffold immune-
compromised NSG and immune-competent BALB/c mice 
and subsequently used in tumor cell invasion assays in vitro 
(Figure 2A). Representative images are provided from tran-
swell Matrigel invasion assays, showing invading MDA-MB-231 
and 4T1 tumor cells cultured in unconditioned control, mock 
CD45+ conditioned, and scaffold CD45+ conditioned media 
(Figure 2B). For MDA-MB-231 cells in the invasion assay, a 
baseline of 250.0 ± 14.6 invading cells per image was observed 
using control medium. A significant increase in tumor cell 
invasion was observed for tumor cells cultured in mock CD45+ 
conditioned media, with 356.6 ± 20.5 invading cells per image. 
Conversely, a marked decrease in tumor cell invasion was deter-
mined for cells cultured in scaffold CD45+ media compared to 
both control and mock CD45+ media, with 164.8 ± 9.0 invading 
cells per image (Figure 2C). Similarly, using 4T1 cells and the 
BALB/c transplant model, we observed a baseline of 792.2 ± 
15.1 cells per image in the control media, 1037.0 ± 21.9 cells 
in the mock CD45+ media, and 585.3 ± 17.2 cells in the scaf-
fold CD45+ media (Figure 2D). Genes identified in our RNAseq 
analysis and associated with NFκB signaling and cell motility 
were also validated by RT-PCR in MDA-MB-231 cells treated 
with scaffold CD45+ media relative to mock CD45+ media, 
with 6/7 genes displaying the same trends toward down- or 
upregulation (Table S4, Supporting Information). Collectively, 
the secreted factors present in conditioned media from scaffold 
CD45+ immune cells induce less invasion relative to the mock 
CD45+ immune cells.
2.3. Scaffolds Alter the Tumor-Associated CD45+  
Cell Secretome and Resulting Transcription Factor  
Activity of In Vitro MDA-MB-231 Cells
We sought to identify secreted factors present in the mock and 
scaffold CD45+ media that might mediate the differential phe-
notypes observed with the invasion assay. CD45+ immune cells 
from mock and scaffold PTs were collected via fluorescence 
activated cell sorting (FACS) and cultured in vitro to generate 
Adv. Healthcare Mater. 2018, 7, 1700903
Figure 1. Transcriptomics analysis of primary tumor cells reveal differentially regulated genes and signaling pathways in response to PLG scaffold 
implants. A) Schematic of experimental design. B) Volcano plot showing 892 genes (in red) with most significantly altered gene expression of scaffold 
PT cells relative to mock PT cells (n = 3, p < 0.01, FDR < 0.1). A complete list of significantly altered genes is provided in Table S1 (Supporting Informa-
tion). C,D) Metascape analysis of C) upregulated and D) downregulated genes (p < 0.01, FDR < 0.1).
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conditioned media, which was subsequently analyzed using 
secretomics techniques. A total of 947 proteins were identi-
fied in both mock and scaffold CD45+ media, with at least one 
peptide spectral match (PSM) in each biological replicate. Of 
the 974 proteins identified, 161 proteins were identified as 
secreted factors. From this secreted factor pool, nine proteins 
had a log2 fold change greater than 1.5 in the mock CD45+ 
media, and seven proteins had a log2 fold change greater than 
1.5 in the scaffold CD45+ media (Figure 3A). A summary of the 
PSM values, the log2 fold changes, and the highlighted secreted 
factor targets in each media is provided (Table S5, Supporting 
Information). Using enzyme linked immunosorbent assays 
(ELISAs) to validate select secretomics results, we confirmed 
the increased abundance of CCL2 and decorin in mock and 
scaffold CD45+ media, respectively. CCL2 had a concentration 
of 241.8 ± 24.3 pg mL−1 in mock CD45+ media compared to 
108.4 ± 18.7 pg mL−1 in scaffold CD45+ media (Figure 3B). 
Decorin had an increased concentration of 448.4 ± 39.0 pg mL−1 
in scaffold CD45+ media relative to 312.8 ± 24.7 pg mL−1 in 
mock CD45+ media (Figure 3C). These results suggest that the 
CD45+ conditioned media from scaffold mice have altered pro-
tein compositions that may contribute to modulating metastatic 
cell invasion.
We subsequently investigated the activity of multiple tran-
scription factors (TFs) in response to the conditioned media, 
which reflect the signaling pathways stimulated by factors 
in the conditioned media. TF activity in MDA-MB-231 cells 
cultured in scaffold CD45+ versus mock CD45+ media was 
measured using TRACER. The transactivation profiles of 
15 TF reporter constructs over a period of 8 h were deter-
mined by normalizing TF activity of cells cultured in scaffold 
CD45+ media compared to mock CD45+ media (Figure S1, 
Supporting Information). Of the 15 reporters tested, 4 TF 
reporters had significantly altered activity when cultured in 
scaffold CD45+ media (Figure 3D). One reporter, GATA1, 
had increased activity in scaffold CD45+ compared to mock 
CD45+ media. Three reporters had decreased activity in 
response to scaffold CD45+ media, including NFκB, retinoic 
acid receptor (RAR), and serum response factor (SRF). The 
decrease in both NFκB and SRF activities would be consistent 
with partial antagonism of epidermal growth factor receptor 
(EGFR) and vascular endothelial growth factor receptor 2 
(VEGFR2) by decorin.[26] Moreover, we noted that 13 target 
genes of SRF and 23 target genes of NFκB were among the 
differentially regulated genes identified by RNAseq (Table S6, 
Supporting Information). Interestingly, only three genes of 
SRF and seven genes of NFκB were downregulated; thus, the 
dynamic signaling of these transcription factors could not 
have been deduced by gene expression analysis alone. The 
four TF reporters with significantly altered activity have been 
previously reported as mediators of tumor cell motility and 
invasion.[27–31]
Adv. Healthcare Mater. 2018, 7, 1700903
Figure 2. CD45+ immune cell conditioned media from mock and scaffold mice alter MDA-MB-231 and 4T1 cell invasion. A) Schematic of experimental 
design. B) Representative bright-field images of invading tumor cells in various media. Scale bar on all images indicate 500 µm. C,D) Tumor cell inva-
sion counts in Control, mock CD45+ conditioned media, and scaffold CD45+ conditioned media (n = 12) for C) MDA-MB-231 and D) 4T1 tumor cells. 
Letters “a,” “b,” and “c” denote groups that are statistically distinct (p < 0.05) according to the one-way ANOVA with Bonferroni testing for multiple 
comparisons. Data are shown as box-and-whisker plots with minimum values, maximum values, and interquartile range.
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2.4. Scaffolds Alter Phenotype of Macrophage Subpopulations 
at the Primary Tumor
Having established that the tumor and TME of scaffold and mock 
mice exhibit differences in transcriptome, invasive phenotype, 
secretome, and signaling, we investigated whether a difference 
in immune cell type, counts, or phenotype in the TME may pro-
vide mechanistic insight for these findings. Substantially more 
F4/80+CD11b+Ly6C− macrophages reside at the PT compared to 
other tissues, with 66.3 ± 1.9% of leukocytes present compared 
to 0.14 ± 0.04% leukocytes in the lung, 8.5 ± 0.5% leukocytes 
in the spleen, and 7.3 ± 0.8% at the scaffold (Figure 4A). We 
observed a modest reduction in the percent of Gr1+CD11b+Ly6C− 
cells among CD45+ cells at the PT between scaffold and mock 
mice, with 15.0 ± 1.6% for mock and 11.2 ± 0.4% for scaffold 
(Figure 4B). On the other hand, no significant changes in other 
cell populations were observed, including F4/80+CD11b+Ly6C− 
macrophages (68.5 ± 0.9% for mock and 69.9 ± 1.9% for scaffold), 
Ly6C+F4/80− monocytes (6.1 ± 0.5% for mock and 6.0 ± 0.6% 
for scaffold), and CD11c+ dendritic cells (5.5 ± 0.6% for mock 
and 5.9 ± 0.6% for scaffold). In the BALB/c model, no signifi-
cant changes were observed in innate and adaptive immune cell 
populations (Figure S2, Supporting Information).
With macrophages being the major cell type in the PT, we sub-
sequently investigated the macrophage source and phenotype 
in the PT for mock and scaffold conditions. TAMs have been 
reported to consist of both tissue-resident macrophages and 
recruited macrophages that originate as CCR2+ monocyte pre-
cursors prior to infiltration of the tumor and subsequent differ-
entiation into macrophages.[3,32] Recruited macrophages express 
the adhesion protein Vcam1 and drive tumor invasion whereas 
resident macrophages are generally considered benign.[3] We 
gated live CD45+ cells as F4/80+Vcam1+ (denoted as F+/V+, 
recruited macrophages), F4/80+Vcam1− (F+/V−, resident macro-
phages), or F4/80−Vcam1− (F−V−, other leukocytes) and sorted 
these populations (Figure 4C). Relative quantities of each leuko-
cyte population did not differ significantly between conditions, 
indicating that the recruitment of cells to the PT is similar for 
scaffold and mock mice (Figure 4D).
Macrophage populations were next transcriptionally analyzed 
to further validate phenotypic changes in recruited macrophage 
populations (Table S7, Supporting Information). F+/V+ macro-
phages exhibited a significant increase in Lyve1, MafB, and 
CD163 and a concomitant decrease in MHCII and Ym1 relative 
to F+/V− macrophages across the board, consistent with their 
identity as a distinct, monocyte-derived macrophage subset. 
Comparing how these recruited F+/V+ macrophages modified 
their transcriptome with respect to their resident macrophage 
counterparts, CCR2 and CCL7 were not significantly different 
in the mock TME but upregulated in the scaffold TME, whereas 
Adv. Healthcare Mater. 2018, 7, 1700903
Figure 3. Scaffold implants alter the CD45+ immune cell secretome, which changes transcription factor activity in MDA-MB-231 cells. A) Scatter plot 
showing the average peptide spectral match (PSM) values of 161 secreted factors present in both CD45+ mock and scaffold media (n = 3). The red 
points represent PSM values with a log2 fold change greater than 1.5 in the scaffold CD45+ media, and the blue points represent PSM values with a 
log2 fold change greater than 1.5 in the mock CD45+ media. A complete list of identified secreted factors is provided in Table S2 (Supporting Informa-
tion). B) Concentration of CCL2 measured using ELISA in mock and scaffold CD45+ media (n = 12), *p < 0.001. C) Concentration of decorin measured 
using ELISA in mock and scaffold CD45+ media (n = 12), *p < 0.01. Data are shown as box-and-whisker plots with minimum values, maximum values, 
and interquartile range. D) Heat map of normalized TF activity values for MDA-MB-231 cells cultured in scaffold CD45+ conditioned media relative 
to mock CD45+ conditioned media over 8 h. Significant changes in TF activity for at least one time point indicated in bold (n = 3 arrays, n = 12 total 
measurements per time point, p < 0.05).
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Vcam1 was more significantly upregulated in the mock condi-
tion than the scaffold condition (Figure 4E). Furthermore, in 
recruited F+/V+ cells compared to F+/V− resident cells, arginase 
(Arg) was upregulated in the scaffold TME but downregulated 
in the mock TME, whereas Itgb5 was downregulated in both 
conditions but more significantly in the scaffold condition and 
MMP9 was downregulated in the mock condition but com-
parable in both populations in the scaffold condition. Taken 
together, these results suggest that F+/V+ cells have a distinct 
functional phenotype in scaffold-implanted mice relative to 
mock mice at the PT, indicating that the scaffold may influence 
the phenotype of the immune cells within the PT.
3. Discussion
In this report, we demonstrate that implanted scaffolds 
affect systemic immune responses, with modulation of the 
secretomic and transcriptional profiles of immune cells in 
the TME, and, consequently, induce phenotypic changes in 
PT cells. Our prior work[13–15] explored the concept of using a 
polymer scaffold to serve as a sink to capture disseminating 
tumor cells, thereby reducing tumor burden in host organs that 
are standard sites of breast cancer metastasis and improving 
host survival.[16] Immune cells present at the scaffold partially 
mediate tumor cell attraction to the implant site. Our results 
suggest that scaffold-mediated redirection of immune cells 
also impacts the PT and the TME. In both immune-competent 
and immune-compromised models, secreted factors from PT 
immune cells in scaffold-implanted mice reduced tumor cell 
invasion in vitro relative to factors from control PT immune 
cells. The reduction in invasion observed using scaffold CD45+ 
media was consistent with a distinct secretome, and reflects the 
transcriptomic differences that were observed in PT cells from 
scaffold-implanted relative to control mice.
We initially determined our biomaterial scaffolds influ-
ence both the in vivo tumor transcriptome and immune cell 
secretome. Without a scaffold, we identified CCL2 in the mock 
CD45+ conditioned media (among other factors), which may 
increase in vitro tumor cell invasion (Figure 2) and suggests 
enhanced invasion in vivo. CCL2 expressed in the tumor stroma 
recruits CCR2-expressing inflammatory monocytes, which are 
known to mediate tumor cell invasion and metastasis.[33] As 
such, the unperturbed TME may contain factors that promote 
immunosuppression and ultimately promote tumor cell inva-
sion and eventual metastasis.[33–35] In response to the scaffold, 
Metascape analysis of the downregulated genes identified mole-
cular functions and pathways suggestive of reduced invasive and 
metastatic capacity of the PT cells. RT-PCR analysis of a subset 
of genes identified in our RNAseq analysis and associated with 
NFκB signaling and cell motility showed modest fold changes 
in expression; however, our functional assays of cell migration 
and NFκB transcription factor activity confirmed downregu-
lation of all these pathways, as the RNAseq pathway analysis 
suggested. Additionally, we identified decorin as a protein sig-
nificantly more abundant in scaffold CD45+ media. Decorin, a 
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Figure 4. Characterization of immune cell populations and phenotypes at the primary tumor in response to scaffold implants. A) Percent of CD45+ 
leukocytes (Gr1hiCD11b+Ly6C− MDSCs, Ly6C+F4/80− inflammatory monocytes, CD11c+ dendritic cells, and F4/80+CD11b+ macrophages) present in 
different tissues from PLG implanted mice (n = 5). B) Percent of CD45+ leukocytes present at the PT from mock surgery and PLG scaffold-implanted 
mice (n = 5, *p < 0.05). C) Gating strategy for stratifying macrophage populations (F4/80+Vcam1+ (denoted as F+/V+, recruited macrophages), 
F4/80+Vcam1− (F+/V−, resident macrophages), or F4/80−Vcam1− (F−V−, other leukocytes)). D) Percent of leukocytes for each macrophage population 
(n = 5). Data are shown as mean ± SEM. E) Fold change in invasion and metastasis associated genes in recruited versus resident TAM populations in 
mock and scaffold mice (n = 6). All genes shown at a confidence level of 90% or higher, with *p < 0.05, **p < 0.01 according to the Student’s t-test.
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leucine-rich proteoglycan present in the ECM, has been shown 
to reduce metastatic spreading of breast cancer through down-
regulation of EGFR activity.[36–38] Further studies have demon-
strated that decorin is known to sequester growth factors such 
as transforming growth factor beta (TGFβ) and suppress pro-
metastatic activity.[39] Collectively, our transcriptomics analysis 
of the tumor cells and secretomics analysis of the CD45+ cells 
suggest the TME is sensitive to systemic effects from the PLG 
scaffold implant and may influence tumor cell invasiveness.
Secreted factors identified in the scaffold TME stimulated 
distinct signaling patterns associated with inhibiting tumor cell 
invasion. Significant decreases were observed in TF activity for 
NFκB, RAR, and SRF reporters in tumor cells treated with scaf-
fold CD45+ media using our TRACER arrays. Previous work 
demonstrates a significant role for NFκB in the inflammation 
response, as well as in regulating EMT and invasion processes 
in metastatic cells. NFκB signaling assists in blocking the 
degradation of Snail in metastatic cells during inflammation-
mediated metastasis, another transcription factor critical for 
initiating EMT.[40] Likewise, RAR activity has been implicated in 
cholangiocarcinoma progression, demonstrating that increased 
RAR activity assists in tumor invasion.[41] Previous work has 
also shown that depletion of SRF activity reduces MDA-MB-
231 cell invasion in vitro and reduces tumor cell colonization 
to the lung in vivo.[30] Moreover, SRF is a downstream factor in 
extracellular signal-regulated kinase/mitogen-activated protein 
kinase (ERK/MAPK) signaling, which is repressed by decorin 
antagonizing VEGFR2.[42] Previous work claims the NFκB p65 
subunit interacts with SRF to influence gene expression down-
stream of the serum response element (SRE) promoter,[43,44] 
corroborating our observation that NFκB and SRF activity 
are linked and decrease in response to scaffold CD45+ media. 
Taken together, reduced NFκB, RAR, and SRF activities suggest 
tumor cells may have reduced invasive capacity in response to 
the scaffold. More broadly, our transcriptomic, secretomic, and 
TRACER assays provide complementary and convergent data 
on an overall network governing tumor cell invasion and the 
contributions of microenvironmental cues.
Our results suggest that changes in tumor cell phenotype are 
likely not due to fluctuations in immune cell recruitment to the 
PT. We initially hypothesized that the implanted scaffold would 
influence Gr1hiCD11b+Ly6C− cell trafficking at the PT, given 
the scaffold’s ability to attract Gr1hiCD11b+Ly6C− and tumor 
cells away from target organ sites.[16] Additionally, given the 
observed decrease in CCL2 in the scaffold CD45+ secretome, we 
also expected lower counts of inflammatory monocytes[33] and 
a lower number of Vcam1+ macrophages in the scaffold PT, as 
they derive from CCR2+ monocytes.[3] Given the minor changes 
in immune cell trafficking, coupled with the high abundance of 
F480+CD11b+ macrophages at the PT relative to other cell types, 
we sought to evaluate potential effects of the scaffold implant on 
TAM phenotype. TAMs at the PT have been implicated in modu-
lating metastatic disease outcome and are also known to assist 
in metastatic cell invasion.[45–47] Moreover, the subset of macro-
phages that are associated with promoting tumor cell invasion 
is the subset that derives from CCR2+ inflammatory monocytes 
recruited to the TME in response to cues sent out by the tumor.[3] 
Given the role of TAMs in mediating PT cell invasion and the 
relatively high abundance of macrophages in PTs, we suspected 
that changes in TAM phenotype may be responsible for altera-
tions in the TME and PT cells due to the scaffold implant.
Our results demonstrate that the scaffold-influenced TME 
altered the phenotype of recruited TAMs relative to the TME 
in mock surgery mice. We identified a subset of F4/80+Vcam1+ 
TAMs that featured an increase in gene expression of Lyve1, 
MafB, and CD163. MafB is a transcription factor that governs 
macrophage differentiation from monocytic or myeloid precur-
sors, whereas CD163 confirms the monocytic origin and Lyve1 
denotes these macrophages as TAMs.[32] Rather than a decrease 
in the percentage of F4/80+Vcam1+ recruited macrophages, 
we observed a different phenotype marked by higher relative 
expression levels of CCR2 and CCR2-binding CCL7, indicating 
reduced retention of the recruited TAMs.[48] Additionally, the 
observed decrease in Ym1 expression would be consistent with 
the observations that F4/80+Vcam1+ recruited macrophages 
are not of the alternatively activated phenotype.[3] Others have 
observed MHCIIhi and MHCIIlo macrophages in tumors and 
deduced that they represented different macrophage sub-
sets.[32] Furthermore, our results suggest that TAMs from 
scaffold-implanted mice were less adhesive (decreased Itgb5 
and Vcam1), suppressed inflammation (increased arginase), 
and enhanced vascular leakiness at the tumor (relatively higher 
MMP9). Changes in the transcriptomic profile of recruited 
TAMs may be attributed to the presence of a distal biomate-
rial scaffold and correlated with an altered TME secretome and 
diminished tumor cell invasion.
4. Conclusion
In summary, our work suggests that implantation of a bio-
material scaffold can have a systemic impact on immune cell 
phenotype, which was demonstrated through an engineered 
PMN mimic distally modulating the PT and TME. We sug-
gest our PMN mimics can be utilized to evaluate interactions 
between the primary tumor, immune cells, and PMNs.[14] Our 
study focused on the innate immune cells, though the poten-
tial remains that the adaptive immune response may also be 
influenced. In addition to manipulating immune cell pheno-
types and the associated secretome, the scaffold may also alter 
other components of the tumor stroma, including cancer asso-
ciated fibroblast phenotype and ECM composition. Additionally, 
PMN mimics may serve as “oncomaterials” for their potential 
clinical applications,[17] which is based on results in mice that 
indicate the ability for early detection of metastatic disease[15] 
and reducing tumor burden.[16,18] Future work may entail moni-
toring the trafficking of immune cells influenced by the tumor 
and scaffold in real time for precision medicine applications.[49] 
Recent approaches in monitoring the immune response at 
implanted scaffolds in vivo using intravital imaging may be 
useful for determining immune cell trafficking over time at both 
the implant and tumor.[50] Real-time evaluation of the immune 
response may further establish that the scaffold modulates the 
TME, and determine whether the scaffold’s alteration of the 
TME can be leveraged to counter tumor progression in vivo. Col-
lectively, our current results suggest that PLG scaffolds have an 
active role in modulating tumor burden and may provide a foun-
dation for developing an effective implantable therapeutic tool.
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5. Experimental Section
Tumor Inoculation: Animal studies were performed in accordance with 
institutional guidelines and protocols approved by the Northwestern 
University Institutional Animal Care and Use Committee. Tumor 
inoculation was performed by injecting 2 × 106 tdTomato+ MDA-MB-
231BR or 4T1 cells in a volume of 50 µL phosphate buffered saline 
(PBS) (Life Technologies) into the number four right mammary fat pads 
of female NSG or BALB/c mice.[15,16] Mice were purchased from The 
Jackson Laboratory or bred in house.
Scaffold Fabrication and Implantation: PLG scaffolds were fabricated 
as previously described.[15] Briefly, microspheres were prepared by 
emulsifying a 6% solution of PLG (Lakeshore Biomaterials; 75:25 
lactide:glycolide, inherent viscosity = 0.76 dL g−1) in dicholoromethane 
in 1% poly(vinyl alcohol) (PVA). Microspheres were washed four times 
with deionized water to remove residual PVA and lyophilized overnight. 
Next, microspheres were mixed with 250–425 µm salt particles in a 30:1 
ratio and pressed in a steel die at 1500 psi. The scaffolds were then gas-
foamed, and salt particles were removed by washing in water for 90 min. 
Scaffolds were sterilized with 70% ethanol and rinsed with water before 
drying. Scaffolds were implanted in the intraperitoneal fat pads 7 d post-
tumor inoculation. Mock surgeries were performed by extracting and 
reinserting the fat pads back into the abdomen without implants.
Primary Tumor Immune Flow Cytometry: For analysis of leukocyte 
populations, tumors were harvested, minced, and treated with a 1× triple 
enzyme mix (10 mg mL−1 collagenase IV, 1 mg mL−1 hyaluronidase, 
and 200 units mL−1 of DNAse in Hank’s balanced salt solution) or 
1× Liberase TM (Roche). Triple-enzyme-treated minced tissue was 
incubated for 1 h, and centrifuged at 50 × g to remove undigested tissue. 
The supernatant was centrifuged at 500 × g to obtain a suspension of 
PT cells. Liberase -treated tissue was incubated for 20 min at 37 °C 
and then neutralized with 0.125 m ethylenediaminetetraacetic acid 
(EDTA) and mashed through a 70 µm cell sieve. Cells were blocked 
with anti-CD16/32 (1:50, Biolegend) and stained for viability using blue 
fixable UV dead cell stain kit (Life Technologies). Cells were then stained 
with AlexaFluor 700-conjugated anti-CD45 (30- F11, 1:125; Biolegend), 
Pacific Blue-conjugated anti-Gr1 (RB6-8C5, 1:70; Biolegend), APC Cy7-
conjugated anti-Ly-6C (HK1.4, 1:70; Biolegend), PE Cy7-conjugated anti-
F4/80 (BM8, 1:70; Biolegend), AlexaFluor 647-conjugated anti-CCR7 
(4B12, 1:25; Biolegend), AlexaFluor 488-conjugated anti-CD206 (15-2, 
1:50; Biolegend), and V500 AmCyan-conjugated anti-CD11b (M1/70, 
1:70; eBioscience). Samples were analyzed using an LSR II flow 
cytometer (BDIS). Flow output data were gated and quantified using 
FlowJo software (Tree Star). Plotting and Student t-test statistical 
analysis were performed using GraphPad Prism.
Macrophage Subset Sorting: Single cell suspensions of tumor cells were 
blocked with anti-CD16/32 (1:50, Biolegend) and stained for viability 
with 4′,6-diamidino-2-phenylindole (DAPI). Cells were then stained with 
AlexaFluor 700-conjugated anti-CD45 (30- F11, 1:125; Biolegend), PE 
Cy7-conjugated anti-F4/80 (BM8, 1:70; Biolegend), and PerCP-Cy5.5-
conjugated anti-Vcam1 (429, 1:125; Biolegend). Live leukocytes were 
collected using DAPI− and CD45+ gates, and then further separated into 
F4/80− Vcam1−, F4/80+ Vcam1−, and F4/80+ Vcam1+ subsets. Samples 
were analyzed using an LSR II flow cytometer (BDIS) and collected in 
TRIzol reagent (Invitrogen) for subsequent transcriptional analysis.
Live CD45+ and tdTomato+ Sorting: For live sorting, single cell 
suspensions of tumor cells were blocked with anti-CD16/32 (1:50, 
Biolegend) and stained for viability using blue fixable UV dead cell 
stain kit (Life Technologies). Cells were then stained with AlexaFluor 
700-conjugated anti-CD45 (30-F11, 1:125; Biolegend) and PE Cy7-
conjugated anti-F4/80 (BM8, 1:70; Biolegend). For CD45+ leukocyte 
collection, single color controls were used to gate BlueFixable−CD45+ 
cells. Live tumor cells were collected using BlueFixable− and tdTomato+ 
gates. Live cells were collected in Roswell Park Memorial Institute 
(RPMI) 1640 media supplemented with 50% fetal bovine serum (FBS) 
and 1% penicillin–streptomycin.
CD45+ Conditioned Media Preparation: For large batches of CD45+ 
media, tumor cells were stained with magnetic CD45+ beads (Miltenyi 
Biotech) and separated using magnetic activated cell sorting (MACS) 
per the manufacturer’s specifications. Briefly, cells were counted and 
incubated with the CD45+ magnetic beads for 10 min. Cells were washed 
with MACS buffer and resuspended at a concentration of no more 
than 108 labeled cells per column. CD45+ cells were collected from the 
column and resuspended at a concentration of 106 cells mL−1 of serum-
free RPMI. Cells were cultured for 48 h to condition the media. Media 
were collected, passed through a 0.22 µm filter, aliquoted, and stored at 
−80 °C before use.
Invasion Assays: The human breast carcinoma cell line MDA-MB-
231 or the mouse mammary carcinoma cell line 4T1 was used for all 
in vitro experiments. Cells were routinely cultured on tissue culture 
polystyrene flasks in RPMI media supplemented with 10% FBS, 1% 
penicillin–streptomycin solution, 1% nonessential amino acids, and 1% 
sodium pyruvate (Life Technologies). Media were exchanged every other 
day. Once ≈80% confluent, cells were harvested with TrypLE Express 
(Life Technologies) solution and counted using a Trypan blue stain 
(Sigma Aldrich) and a Cell Countess automated hemocytometer (Life 
Technologies). All cells were cultured in a humidified 5% CO2 incubator 
at 37 °C.
For all invasion assays, confluent cultures of MDA-MB-231 or 4T1 
cells were serum starved overnight in serum-free RPMI supplemented 
with 1% penicillin–streptomycin solution, 1% nonessential amino acids, 
and 1% sodium pyruvate prior to harvesting. Invasion assays were 
performed using Matrigel-coated transwell chambers with 8 µm pores 
(BD Biosciences). The membranes were hydrated with serum-free media 
for 1 h before plating cells. Serum-free cell suspensions were prepared 
and plated in transwell inserts at a density of 50,000 cells per insert. 
Inserts were then placed in unconditioned RPMI media, mock CD45+ 
conditioned media, or scaffold CD45+ conditioned media supplemented 
with 2.0% FBS. Transwell inserts with cells were incubated for 24 h in a 
humidified 5% CO2 incubator at 37 °C. After the incubation period, the 
cells on the top of the membrane were scraped away using a cotton swab 
soaked in PBS. Cells were fixed and stained in a 0.5% w/v crystal violet 
solution using a 60% EtOH/40% PBS solvent. Cells were imaged directly 
on the membrane with a Nikon Eclipse inverted microscope, and imaged 
at 10×. Four images per well were captured (n = 4) and cell numbers 
were quantified using ImageJ. All experiments were performed in 
triplicate and pooled together (n ≥ 12). Statistical analysis was performed 
in GraphPad Prism, using one-way analysis of variance (ANOVA) with 
Bonferroni testing for multiple comparisons.
Quantitative RT-PCR Sample Preparation and Analysis: Tumors 
were isolated from n = 6 scaffold and n = 6 mock mice as previously 
described. A minimum of 100,000 cells of each subtype were sorted 
and collected in TRIzol reagent (Invitrogen) and RNA was isolated as 
per the manufacturer’s recommendations. Purified RNA was quantified 
via NanoDrop 2000 (Thermo Scientific) and reverse transcribed using 
the iScript cDNA synthesis kit (BioRad). Samples were then prepared 
in technical duplicate with six biological replicates using the QuantiTect 
SYBR Green PCR Kit (Qiagen) and gene probes (Tables S2 and S7, 
Supporting Information). Quantification was performed using an ABI 
7900 HT instrument (Applied Biosystems). Data were analyzed in Excel 
as previously described[51] with nondetects excluded from analysis and 
a reference Cq (defined as the mean of three reference genes, ActB, 
GAPDH, and Rplp0) used to normalize the Cq values of each sample. 
Significance was determined using the Student’s t-test.
Secretomics Sample Preparation, Analysis, and Validation: Secretomics 
analysis was performed as previously described.[14] For secretomics 
analysis, CD45+ cells collected via FACS were washed three times with 
media to ensure sufficient removal of FBS contamination from FACS 
collection media. Approximately 105 live CD45+ cells were cultured in 
500 µL of serum-free media for 48 h. Samples were passed through 
a 0.22 µm filter and protein concentration was measured using a 
NanoDrop 1000 (Thermo Scientific). Samples were stored at −80 °C 
before use.
For each concentrated conditioned media sample (three biological 
replicates), 5 µg of protein was solubilized by adding 8 m urea and 
incubating at 50 °C for 60 min. Following denaturation, proteins were 
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solubilized and reduced by adding 10 × 10−3 m dithiothreitol (DTT) (final 
concentration: 1 × 10−3 m) and incubating at 50 °C for 15 min. After 
reduction, proteins were alkylated by adding 100 × 10−3 m iodoacetamide 
(final concentration: 10 × 10−3 m) and incubated in the dark at room 
temperature for 15 min. Protein samples were digested by diluting the 
8 m urea solution to 1 m by adding 100 × 10−3 m ammonium bicarbonate 
and trypsin. The sample was digested at 37 °C overnight. The digested 
samples were desalted using reverse phase C18 spin columns (Thermo 
Fisher Scientific). After desalting, the peptides were concentrated 
in vaccuo until dry. After drying, peptides were suspended in 5% 
acetonitrile and 0.1% formic acid. The samples were loaded directly onto 
a 15 cm long, 75 × 10−6 m reversed phase capillary column (ProteoPep II 
C18, 300 Å, 5 µm size, New Objective) and separated using a 200 min 
gradient from 5% acetonitrile to 100% acetonitrile on a Proxeon Easy 
n-LC II (Thermo Scientific). The peptides were eluted into an LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific) with electrospray 
ionization at a 350 nL min−1 flow rate. The mass spectrometer was 
operated in data-dependent mode. For each MS1 precursor ion scan, 
the ten most intense ions were selected for fragmentation by collision-
induced dissociation. Additional parameters for mass spectrometry 
analysis included setting the resolution of MS1 at 60,000, the normalized 
collision energy at 35%, the activation time at 10 ms, and the isolation 
width at 1.5. Charge states +4 and higher were rejected.
The data were processed using Proteome Discoverer (version 
1.4, Thermo Scientific) and searched using embedded SEQUEST HT 
search engine. The data were searched against a mouse reference 
proteome (September 2013, Uniprot). Additional search parameters 
were as follows: (i) enzyme specificity: trypsin, (ii) fixed modification: 
cysteine carbamidomethylation, (iii) variable modification: methionine 
oxidation and N-terminal acetylation, (iv) precursor mass tolerance was 
±10 ppm, and (iv) fragment ion mass tolerance was ±0.8 Da. All the 
spectra were searched against target/decoy databases and results were 
used to estimate the q values with the Percolator algorithm embedded 
in Proteome discoverer 1.4. The peptide identification was considered 
valid at q value < 0.1 and was grouped for protein inference to satisfy the 
rule of parsimony. Further, each protein in the final identification list was 
considered valid if supported with a minimum of one unique peptide.
Proteins were quantified using spectral counting[52] and normalized 
spectral abundance factors (NSAF).[53,54] The NSAF normalization takes 
into consideration of the length of the protein, which may result into 
higher spectral count per protein. Initially, the total number of spectral 
counts (spc) per protein was divided by the peptide length (L), and then 
divided by the sum (∑ spc/L) of all the values in the sample. Proteins 
were determined significantly changed with a t-test (significance level of 
p < 0.05) and a log2 fold change greater than or equal to 1.5.
ELISAs were performed per the manufacturer’s protocol. Conditioned 
media samples were directly added to CCL2 and decorin ELISA 
plates (Abcam) and absorbance at 450 nm was used to determine 
concentration using a standard curve.
CD45+ Conditioned Media TRACER Arrays: TRACER arrays were 
performed as previously described.[14,55] Harvested MDA-MB-231 cells 
were diluted to a final concentration of 50 cells µL−1. About 400 µL of 
this suspension was aliquoted into separate 1.5 mL Eppendorf tubes for 
viral infection. The aliquot was mixed with lentiviral vectors containing 
TF reporter constructs at a multiplicity of infection of approximately 
ten virions per cell. Cells and virus were mixed and plated at 2000 cells 
per well in a black, clear bottom, 384-well plate (Greiner Bio-One). 
Cells plated without virus infection served as negative controls for 
nonenzymatic DLuc degradation. A positive control consisting of a 
TA-FLuc reporter construct without any additional TF binding elements 
was used to determine basal promoter activity. Each TF reporter is 
represented with n = 4 measurements per array plate, and arrays 
were repeated a total of six times. After infection, cells were incubated 
for 48 h.
To measure TF activity, d-luciferin (DLuc, RR Labs, Inc.) diluted in 
the appropriate media (mock CD45+ or scaffold CD45+) was added to 
wells in excess at a final concentration of 2 × 10−3 m. After a 45 min 
incubation period with the DLuc, the luminescence was quantified using 
an IVIS Lumina LTE imaging system (Caliper Life Sciences). Cells plated 
without virus infection served as negative controls for nonenzymatic 
DLuc degradation. A positive control consisted of a TA-FLuc reporter 
construct without any additional TF-binding elements, which was 
used to determine basal promoter activity. All luminescence readings, 
measured in photon flux (photons per second), were normalized to 
the TA luminescence. On Day 0, cells were treated with either mock 
or scaffold CD45+ media containing 2 × 10−3 m of DLuc and 10% FBS. 
Bioluminescence imaging was conducted every 2 h, and five reads were 
taken in 1 d. Each TF reporter was represented with n = 4 measurements 
per array plate, and arrays were repeated three times.
Initial methodology to normalize and determine statistical 
significance was slightly modified.[56] Array data were log2 transformed 
and filtered to eliminate all intensities below background (p < 0.05). The 
background was defined as the mean measured intensity in noninfected 
cells subject to the same treatment at the same time and plate. At each 
time point, the TA control reporter and the control condition were used 
to normalize reporter activity to calculate the fold change in TF activity 
of cells cultured in scaffold CD45+ media relative to mock CD45+ media. 
Normalized values that were identified to be outliers (p < 0.003) for each 
reporter were removed.
Normalized log2 TF activity fold change of MDA-MB-231 cells cultured 
in scaffold versus mock CD45+ media was compared using the limma 
package in R.[57] A linear model was fit to the normalized log2 values for 
each TF and was used to generate estimated coefficients and squared 
errors (SEs) for each time point of the compared samples. The estimated 
coefficients and SEs were then used to compute moderated t-statistics, 
moderated F-statistics, and log-odds of differential expression. FDR 
was used to correct for multiple comparisons. TFs identified to be 
differentially active had an adjusted p-value of less than 0.05.
RNAseq Preparation, Library Construction, and Sequencing: RNA 
samples were obtained from FACS collected tdTomato+ tumor cells (n = 3 
mock and n = 3 scaffold) using an RNeasy MiniKit (Qiagen) according 
to the manufacturer’s protocol. RNA concentration was quantified using 
a NanoDrop 1000, and RNA samples were stored in −80 °C until further 
use. RNA quality was assessed using an Agilent 2100 Bioanalyzer.
The Beijing Genomics Institute performed the library construction 
(100 bp, paired end) and sequencing. The total RNA samples were 
enriched using oligo(dT) magnetic beads. Mixed with the fragmentation 
buffer, the mRNA was fragmented into short fragments of about 200 bp. 
Then, the first strand of cDNA was synthesized using random hexamer-
primer. Buffer, dNTPs, RNase H, and DNA polymerase I were added to 
synthesize the second strand. The double stranded cDNA was purified 
with magnetic beads. End reparation and 3′-end single nucleotide A 
(adenine) addition were then performed. Finally, sequencing adaptors 
were ligated to the fragments. The fragments were enriched by PCR 
amplification. During the QC step, Agilent 2100 Bioanalyzer and ABI 
StepOnePlus Real-Time PCR System were used to qualify and quantify 
the sample libraries. Finally, the library products were sequenced on the 
Illumina HiSeq2000.
Transcriptome Analysis: The quality of DNA reads, in fastq format, 
was evaluated using FastQC. Adapters were removed and reads of 
poor quality were filtered. The data were processed largely following the 
procedure previously described.[58] Briefly, the reads were aligned to the 
Homo sapiens genome (hg19) using TopHat (v2.0.8b). Subsequently, 
the aligned reads, in conjunction with a gene annotation file for hg19 
obtained from the UCSC website, were used to determine the expression 
of known genes using Cufflinks (v2.1.1). The individual transcript files 
generated by Cufflinks for each sample were merged into a single gene 
annotation file, which was then used to perform a differential expression 
analysis with the Cufflinks routine, cuffdiff. Differential expression 
was determined by cuffdiff using a p-value cutoff value of 0.01.[58] The 
results of the differential expression analysis were processed with 
cummeRbund. Gene ontology and pathway analysis was performed 
on upregulated and downregulated genes separately with significance 
threshold of p < 0.01 and FDR < 0.1 using Metascape.[59]
Statistical Analysis: Data were shown as mean ± standard error (SEM) 
unless otherwise noted. Significance was claimed for p-values less 
Adv. Healthcare Mater. 2018, 7, 1700903
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1700903 (10 of 11)
www.advancedsciencenews.com www.advhealthmat.de
than 0.05, as determined using unpaired Student’s t-tests for single 
comparisons or one-way ANOVA with Bonferroni testing for multiple 
comparisons unless otherwise noted. Statistical analysis was performed 
in GraphPad Prism unless otherwise noted. Sample sizes and data 
preprocessing differed by experimental methodology and are discussed 
in the respective experimental subsections and figure legends.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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